Costimulation by CD137/4-1BB inhibits T cell apoptosis and induces Bcl-xL and c-FLIP(short) via phosphatidylinositol 3-kinase and AKT/protein kinase B.
about
Breaking Free of Control: How Conventional T Cells Overcome Regulatory T Cell Suppression.The advantages of PD1 activating chimeric receptor (PD1-ACR) engineered lymphocytes for PDL1(+) cancer therapySynthetic glycosidated phospholipids induce apoptosis through activation of FADD, caspase-8 and the mitochondrial death pathway.Versatile strategy for controlling the specificity and activity of engineered T cells.Transgenic 4-1BBL-engineered vaccine stimulates potent Gag-specific therapeutic and long-term immunity via increased priming of CD44(+)CD62L(high) IL-7R(+) CTLs with up- and downregulation of anti- and pro-apoptosis genes.c-IAP ubiquitin protein ligase activity is required for 4-1BB signaling and CD8(+) memory T-cell survival.Impaired apoptosis of megakaryocytes and bone marrow mononuclear cells in essential thrombocythemia: correlation with JAK2V617F mutational status and cytoreductive therapy.Adenoviral Vector Vaccination Induces a Conserved Program of CD8(+) T Cell Memory Differentiation in Mouse and Man.NKT cell costimulation: experimental progress and therapeutic promiseHIV-specific CD8+ T cells from elite controllers are primed for survival.Immune regulation and control of regulatory T cells by OX40 and 4-1BBEnhanced T cell apoptosis within Drak2-deficient mice promotes resistance to autoimmunityTumor evasion from T cell surveillance.Regulation of PI-3-Kinase and Akt Signaling in T Lymphocytes and Other Cells by TNFR Family MoleculesTargeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy.Targeting tumor-necrosis factor receptor pathways for tumor immunotherapyThe future of cancer treatment: immunomodulation, CARs and combination immunotherapy.CD134-allodepletion allows selective elimination of alloreactive human T cells without loss of virus-specific and leukemia-specific effectorsCurrent modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines.Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication.Triple expression of B7-1, B7-2 and 4-1BBL enhanced antitumor immune response against mouse H22 hepatocellular carcinoma.Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein.Adoptive immunotherapy using T lymphocytes redirected to glypican-3 for the treatment of lung squamous cell carcinomaThe adaptation model of immunity.Crystal structure of murine 4-1BB and its interaction with 4-1BBL support a role for galectin-9 in 4-1BB signaling.A disintegrin and metalloprotease-17 and galectin-9 are important regulators of local 4-1BB activity and disease outcome in rheumatoid arthritis.Optimization of in vitro expansion of macaque CD4 T cells using anti-CD3 and co-stimulation for autotransfusion therapy.
P2860
Q26744624-6912131F-7342-46C2-886C-0DC20A97B7C3Q28646882-CF7CDE13-5FBA-4923-84D1-3865918C8140Q33855963-46E599D8-94A1-45B5-837E-3F60B37A9244Q34045831-14F500D4-E48E-491F-912E-93D879977141Q35833636-F7D777FB-3108-4ABE-B00F-D6E2994C7462Q36037485-73DC93C4-6FFF-49AA-97B0-2F21C73FED95Q36303858-F818C0EA-88B4-496E-B263-2D50A5E520D4Q36349755-142D8D35-50D6-49DC-97DB-9C23C8AAA6BBQ36739843-6DA1CFEB-8218-40F6-94A6-A0D71464B437Q36760035-FC13B3F2-D27D-423E-B3BF-CBB1046F57F1Q36794126-A6C95CBB-72F9-4C16-BA3E-A6928EA73033Q37260135-EB7C60FF-E38A-465A-B163-AA7BA8B28950Q37970674-308144B9-CC07-4AE4-A6FD-FAC4CCD4BC78Q38113962-9A87E671-BEAF-49E7-8B84-39DFB62E6F91Q38120535-DBB35C13-2D21-499E-9AB9-9AE3AEB9BB5CQ38214095-3370A849-A2C1-4C6E-B22D-9D45C0C65127Q38775177-2602DEEB-9AEA-4C59-A0BB-F862458FF954Q39025319-6545FA75-A388-44E7-87C0-A4D8533D8D43Q39189908-BE3E6186-A195-41D7-9925-58D2E9C92A39Q39641387-B6BD1F7D-1001-4EFB-8272-A3410814E245Q39690697-92ECE637-8B3B-4EA3-9255-A085A7259490Q39791587-77AFDA9F-5D25-422D-9421-144BE60E62ACQ39924228-3AE0EF20-879D-488D-B0BB-8FF6630296ADQ44991707-2BF6DDCB-9467-4D7B-BF71-8324AC7559DEQ47292379-D364B3E9-9A82-411F-8506-3B495B7D2C53Q51689120-36B82D30-3753-4F84-B8A0-CB1AB0D13BB0Q51980648-44CFF4D5-BE13-49A0-B1DD-1969905DF0BE
P2860
Costimulation by CD137/4-1BB inhibits T cell apoptosis and induces Bcl-xL and c-FLIP(short) via phosphatidylinositol 3-kinase and AKT/protein kinase B.
description
2005 nî lūn-bûn
@nan
2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Costimulation by CD137/4-1BB i ...... nase and AKT/protein kinase B.
@ast
Costimulation by CD137/4-1BB i ...... nase and AKT/protein kinase B.
@en
type
label
Costimulation by CD137/4-1BB i ...... nase and AKT/protein kinase B.
@ast
Costimulation by CD137/4-1BB i ...... nase and AKT/protein kinase B.
@en
prefLabel
Costimulation by CD137/4-1BB i ...... nase and AKT/protein kinase B.
@ast
Costimulation by CD137/4-1BB i ...... nase and AKT/protein kinase B.
@en
P2093
P2860
P356
P1476
Costimulation by CD137/4-1BB i ...... nase and AKT/protein kinase B.
@en
P2093
Bernd Dörken
Christian Scholz
Lilian Stärck
Peter T Daniel
P2860
P304
P356
10.1002/EJI.200425686
P407
P577
2005-04-01T00:00:00Z